Literature DB >> 20516376

Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.

Luigi Di Biase1, J David Burkhardt, Prasant Mohanty, Javier Sanchez, Rodney Horton, G Joseph Gallinghouse, Dhanunjay Lakkireddy, Atul Verma, Yaariv Khaykin, Richard Hongo, Steven Hao, Salwa Beheiry, Gemma Pelargonio, Antonio Dello Russo, Michela Casella, Pietro Santarelli, Pasquale Santangeli, Paul Wang, Amin Al-Ahmad, Dimpi Patel, Sakis Themistoclakis, Aldo Bonso, Antonio Rossillo, Andrea Corrado, Antonio Raviele, Jennifer E Cummings, Robert A Schweikert, William R Lewis, Andrea Natale.   

Abstract

BACKGROUND: Catheter ablation of atrial fibrillation is associated with the potential risk of periprocedural stroke, which can range between 1% and 5%. We developed a prospective database to evaluate the prevalence of stroke over time and to assess whether the periprocedural anticoagulation strategy and use of open irrigation ablation catheter have resulted in a reduction of this complication. METHODS AND
RESULTS: We collected data from 9 centers performing the same ablation procedure with the same anticoagulation protocol. We divided the patients into 3 groups: ablation with an 8-mm catheter off warfarin (group 1), ablation with an open irrigated catheter off warfarin (group 2), and ablation with an open irrigated catheter on warfarin (group 3). Outcome data on stroke/transient ischemic attack and bleeding complications during and early after the procedures were collected. Of 6454 consecutive patients in the study, 2488 were in group 1, 1348 were in group 2, and 2618 were in group 3. Periprocedural stroke/transient ischemic attack occurred in 27 patients (1.1%) in group 1 and 12 patients (0.9%) in group 2. Despite a higher prevalence of nonparoxysmal atrial fibrillation and more patients with CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score >2, no stroke/transient ischemic attack was reported in group 3. Complications among groups 1, 2, and 3, including major bleeding (10 [0.4%], 11 [0.8%], and 10 [0.4%], respectively; P>0.05) and pericardial effusion (11 [0.4%], 11 [0.8%], and 12 [0.5%]; P>0.05), were equally distributed.
CONCLUSIONS: The combination of an open irrigation ablation catheter and periprocedural therapeutic anticoagulation with warfarin may reduce the risk of periprocedural stroke without increasing the risk of pericardial effusion or other bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516376     DOI: 10.1161/CIRCULATIONAHA.109.921320

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  62 in total

1.  Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation.

Authors:  Kadri Murat Gurses; Duygu Kocyigit; Muhammed Ulvi Yalcin; Banu Evranos; Hikmet Yorgun; Mehmet Levent Sahiner; Ergun Baris Kaya; Mehmet Ali Oto; Necla Ozer; Kudret Aytemir
Journal:  J Interv Card Electrophysiol       Date:  2015-02-28       Impact factor: 1.900

Review 2.  Meta-analysis of bleeding complications associated with cardiac rhythm device implantation.

Authors:  Michael L Bernard; Matthew Shotwell; Paul J Nietert; Michael R Gold
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-04-24

Review 3.  Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.

Authors:  Abhishek Maan; E Kevin Heist; Jeremy N Ruskin; Moussa Mansour
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

Review 4.  Collateral Damage During Ablation of Atrial Fibrillation - Lessons Learnt in the Past Decade.

Authors:  David Spragg
Journal:  J Atr Fibrillation       Date:  2012-02-02

5.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

6.  [Implantation of Watchman™ occluder of the left atrial appendage. Tips and tricks].

Authors:  Carsten W Israel; Wladimir N Tschishow; Denio Ridjab; Stephan Kische; Julia Buddecke; Hüseyin Ince
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-03

7.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

8.  A bridge too far? Findings of bridging anticoagulation use and outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Amir Y Shaikh; David D McManus
Journal:  Circulation       Date:  2014-12-12       Impact factor: 29.690

9.  [Catheter ablation of paroxysmal atrial fibrillation. Optimal approach and result].

Authors:  Shibu Mathew; Andreas Metzner; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-04-16

10.  Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin.

Authors:  Susumu Tao; Kenichiro Otomo; Yuichi Ono; Yuki Osaka; Tatsuhiko Hirao; Kenji Koura; Tomoko Manno; Daisuke Ueshima; Shigeo Shimizu; Mitsuaki Isobe; Kenzo Hirao
Journal:  J Interv Card Electrophysiol       Date:  2016-12-09       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.